Abstract
Human pharmaceuticals are ubiquitous water contaminants that may have subtle detrimental effects on aquatic organisms, and possibly also on human health. The risks of pharmaceuticals, or pharmaceutically active compounds, remain poorly understood. Awareness of the presence of pharmaceuticals in the environment, coupled with evidence of effects such as fish feminization, however, suggest that precautionary management action to reduce the release of pharmaceuticals to the environment should be considered. The purpose of our study was to evaluate the scope of the issue and possible management strategies from the perspectives of expert stakeholders, drawn from government, academia, and the pharmaceutical and consulting industries, involved in scientific research or policy and management activity, from Canada, the United States, and Europe. Twenty-seven interviewees were asked about their views on management strategies such as pharmaceutical-return programs and incentives for the development of “green” pharmaceuticals. Interviewees generally believed that pharmaceuticals in the environment represented a concern for both human and ecosystem health, although they were more concerned about impacts on aquatic ecosystems. They believed that advanced wastewater treatment technology, education of medical professionals to reduce overprescription, pharmaceutical-return programs coupled with public education, and requirements for all municipalities to have a minimum of secondary wastewater treatment were the most effective management strategies to reduce the environmental impacts of pharmaceuticals. These strategies should be considered by governments interested in managing the risks of human pharmaceuticals in the environment. Combinations of management strategies will likely be most effective in mitigating the risks presented by pharmaceuticals.
Similar content being viewed by others
References
Balcýoðu I. A., M. Ötker. 2003. Treatment of pharmaceutical wastewater containing antibiotics by O3 and O3/H2O2 processes. Chemosphere 50:85–95
Barnes K. K., S. C. Christenson, D. W. Kolpin, M. J. Focazio, E. T. Furlong, S. D. Zaugg, M. T. Meyer, L. B. Barber. 2004. Pharmaceuticals and other organic waste water contaminants within a leachate plume downgradient of a municipal landfill. Ground Water Monitoring Remed 24:119–126
Boxall A. B. A., P. Blackwell, R. Cavallo, P. Kay, J. Tolls. 2002. The sorption and transport of a sulphonamide antibiotic in soil systems. Toxicol Lett 131:19–28
Boyd G. R., H. Reemtsma, G. A. Grimm, S. Mitra. 2003. Pharmaceuticals and personal care products (PPCPs) in surface and treated waters of Louisiana, USA and Ontario, Canada. Science Total Envir 311:135–149
Brain R. A., D. J. Johnson, S. M. Richards, M. L. Hanson, H. Sanderson, M. W. Lam, C. Young, S. A. Mabury, P. K. Sibley, K. R. Solomon. 2004. Microcosm evaluation of the effects of an eight pharmaceutical mixture to the aquatic macrophytes Lemna gibba and Myriophyllum sibiricum. Aquat Toxicol 70:23–40
Canadian Standards Association. 1997. CAN/CSA-Q850-97: Risk management: a guideline for decision-makers, Etobicoke, Ontario, 45 pp
Carballa M., F. Omil, J. M. Lema, M. Llompart, C. García-Jares, I. Rodríguez, M. Gómez, T. Ternes. 2004. Behavior of pharmaceuticals, cosmetics and hormones in a sewage treatment plant. Water Res 38:2918–2926
CEPA. 1999. Canadian Environmental Protection Act. The House of Commons of Canada, Bill C-32, as passed by the House of Commons, June 1, 1999
Christensen F. M. 1998. Pharmaceuticals in the environment—a human risk? Regul Toxicol Pharmacol 28:212–221
Cleuvers M. 2003. Aquatic ecotoxicity of pharmaceuticals including the assessment of combination effects. Toxicol Lett 142:185–194
Cordy G. E., N. L. Duran, H. Bower, R. C. Rice, E. T. Furlong, S. D. Zaugg, M. T. Meyer, L. B. Barber, D. W. Kolpin. 2004. Do pharmaceuticals, pathogens, and other organic waste water compounds persist when waste water is used for recharge? Ground Water Monitoring Remed 24:58–69
Covello V. T. 1989. Informing people about risks from chemicals, radiation, and other toxic substances: a review of obstacles to public understanding and effective risk communication. In Leiss W. (ed.), Prospects and problems in risk communication. University of Waterloo Press, Waterloo, Pages 1–49
CPMP. 2001. Discussion paper on environmental risk assessment of non-genetically modified organisms (non-GMO) containing medicinal products for human use. CPMP/SWP/4447/00, Committee for Proprietary Medicinal Products, London, UK, 9 pp
Datta L-e. 1997. A pragmatic basis for mixed-method designs. In Greene J. C., Caracelli V. J. (eds.), Advances in mixed-method evaluation: the challenges and benefits of integrating diverse paradigms. New directions for evaluation. Jossey-Bass, San Francisco, Pages 33–46
Daughton C. G., T. A. Ternes. 1999. Pharmaceuticals and personal care products in the environment: Agents of subtle change? Envir Health Perspect 107: 907–938
Daughton C. G. 2003a. Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health—Part 1: Rationale and avenues toward a green pharmacy. Envir Health Perspect 111:757–774
Daughton C. G. 2003b. Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. II. Drug disposal, waste reduction, and future directions. Envir Health Perspect 111:775–785
Daughton C. G. 2004. PPCPs in the environment: Future research—beginning with the end always in mind. In K. Kümmerer (ed.), Pharmaceuticals in the environment. Springer-Verlag, Berlin, Pages 463–495
Dizer H., B. Fischer, I. Sepulveda, E. Loffredo, N. Senesi, F. Santana, P. D. Hansen. 2002. Estrogenic effect of leachates and soil extracts from lysimeters spiked with sewage sludge and reference endocrine disrupters. Envir Toxicol 17:105–112
Doerr-MacEwen N. A., M. E. Haight. 2005. Tailoring the precautionary principle to pharmaceuticals in the environment: accounting for experts’ concerns. In A. G. Kungolos, C. A. Brebbia, E. Beriatos (eds.), Sustainable development and planning II (vol. 1). WIT Press, Southampton, Pages 281–291
Eckel W. P., B. Ross, R. K. Isensee. 1993. Pentobarbital found in ground water. Ground Water 31:801–804
FDA. 1998. Guidance for industry: Environmental Assessment of human drug and biologics applications. Government of the United States of America, 33 pp
Fisher P. M. J., R. Borland. 2003. Gauging the pharmaceutical burden on Sydney’s environment: a preventative response. J Cleaner Production 11:315–320
Fong P. P. 1998. Zebra mussel spawning is induced in low concentrations of putative serotonin reuptake inhibitors. Biol Bull 194:143–149
Fong P. P. 2001. Antidepressants in aquatic organisms: a wide range of effects. In C. G. Daughton, T. L. Jones-Lepp (eds.), Pharmaceuticals and personal care products in the environment: scientific and regulatory issues. American Chemical Society, Washington, DC, PP 264–281
Golet E. M., I. Xifra, H. Siegrist, A. C. Alder, W. Giger. 2003. Environmental exposure assessment of fluoroquinolone antibacterial agents from sewage to soil. Envir Sci Technol 37:32–43
Government of British Columbia. 1997. Waste management act: Post-consumer residual stewardship program regulation. B.C. Reg. 111/97, O.C. 333/97
Greene J. C., V. J. Caracelli. 1997. Defining and describing the paradigm issue in mixed-method evaluation. In J. C. Greene, V. J. Caracelli (eds.), Advances in mixed-method evaluation: the challenges and benefits of integrating diverse paradigms. New directions for evaluation. Jossey-Bass Publishers, San Francisco, Pages 5–18
Greene J. C., V. J. Caracelli, W. F. Graham. 1989. Toward a conceptual framework for mixed-method evaluation designs. Educ Eval Policy Analysis 11:255–274
Greiner P., I. Rönnefahrt. 2003. Management of environmental risks in the life cycle of pharmaceuticals. Envirapharma, Lyon
Guardabassi L., A. Petersen, J. E. Olsen, A. Dalsgaard. 1998. Antibiotic resistance in Acinetobacter spp. isolated from sewers receiving waste effluent from a hospital and a pharmaceutical plant. Appl Envir Microbiol 64:3499–3502
Health Canada. 2002. Health Canada to require environmental assessments of products regulated under the Food and Drug Act. http://www.hc-sc.gc.ca/english/media/releases/2001.2001_98e.htm
Health Canada. 2003. Environmental assessment regulations: final issue identification paper. http://www.hc-sc.gc.ca/ear-ree/final_issue_id_2_e.html
Heberer T. 2002. Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. Toxicol Lett 131:5–17
Heberer T., D. Feldmann, K. Reddersen, H. Altmann, T. Zimmerman. 2002. Production of drinking water from highly contaminated surface waters: Removal of organic, inorganic, and microbial contaminants applying mobile membrane filtration units. Acta Hydrochim Hydrobiol 30:24–33
Heberer T., K. Schmidt-Bäumier, H. J. Stan. 1998. Occurrence and distribution of organic contaminants in the aquatic system in Berlin. Part 1: Drug residues and other polar contaminants in Berlin surface and groundwater. Acta Hydrochim Hydrobiol 26:272–278
Holm J. V., K. Rugger, P. L. Bjerg, T. H. Christensen. 1995. Occurrence and distribution of pharmaceutical organic compounds in the groundwater downgradient of a landfill (Grinsted, Denmark). Envir Sci Technol 29:1415–1420
Holtz S. 2006. There is no “away”. Pharmaceuticals, personal care products, and endocrine-disrupting substances: emerging contaminants detected in water. Canadian Institute for Environmental Law and Policy, Toronto, 94 pp
Jobling S., M. Nolan, C. R. Tyler, G. Brightly, J. P. Sumpter. 1998 Widespread sexual disruption in wild fish. Envir Sci Technol 32:2498–2506
Kinney C. A., E. T. Furlong, S. L. Werner, J. D. Cahill. 2006. Presence and distribution of wastewater-derived pharmaceuticals in soil irrigated with reclaimed water. Envir Toxicol Chem 25:317–326
Kolpin D. W., E. T. Furlong, M. T. Meyer, M. E. Thurman, S. D. Zaugg, L. B. Barber, H. T. Buxton. 2002. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999–2000: A national reconnaissance. Envir Sci Technol 36:1202–1211
Krosnick J. A., L. R. Fabrigar. 1997. Designing rating scales for effective measurement in surveys. In L. Lyberg, P. Biemer, M. Collins, E. de Leeuw, C. Dippo, N. Schwarz, D. Trewin (eds.), Survey measurement and process quality. John Wiley & Sons, New York, Pages 141–164
Larsen T. A., J. Lienert, A. Joss, H. Siegrist. 2004. How to avoid pharmaceuticals in the aquatic environment. J Biotechnol 113:295–304
Larsson D. G. J., M. Adolfsson-Erici, J. Parkkonen, M. Pettersson, A. H. Berg, P. E., Olsson, L. Förlin. 1999. Ethinyloestradiol—an undesired fish contraceptive? Aquat Toxicol 45:91–97
McGarvin M. 2001. Science, precaution, facts and values. In T. O’ Riordan, J. Cameron, A. Jordan (eds.), Reinterpreting the precautionary principle. Cameron May, London, Pages 35–60
Metcalfe C. D., X. S. Miao, B. Koenig, J. Struger. 2003. Distribution of acidic and neutral drugs in surface waters near sewage treatment plants in the lower Great Lakes, Canada. Envir Toxicol Chem 22:2881–2889
Mittelstaedt M. 2003. Drug traces found in cities’ water. Page 1 in The Globe and Mail, February 10
Morgan M. G., L. F. Pitelka, E. Shevliakova. 2001. Elicitation of expert judgments of climate change impacts on forest ecosystems. Climatic Change 49:279–307
Oaks J. L., M. Gilbert, M. Virani, R. T. Watson, C. U. Meteyer, B. A. Rideout, H. L. Shaviprasad, S. Ahmed, M. J. I. Chaudhry, M. Arshad, S. Mahmood, A. Ali, A. A. Khan. 2004. Diclofenac residues as the cause of vulture population decline in Pakistan. Nature 427:630–633
O’Brien E., D. R. Dietrich. 2004.Hindsight rather than foresight: reality versus the EU draft guideline on pharmaceuticals in the environment. TRENDS Biotechnol 22:326–330
O’Connor D. R. 2002. Report of the Walkerton inquiry: the events of May 2000 and related issues, Part I. Government of Ontario, Toronto, 188 pp
Purdom C. E., P. A. Hardiman, V. J. Bye, N. C. Eno, C. R. Tyler, J. R. Sumpter. 1994. Estrogenic effects of effluents from sewage treatment works. Chem Ecol 8:275–285
Product Stewardship Institute. 2004a. PSI Pharmaceuticals Project. http://www.productstewardship.us/prod_pharm_project.html
Product Stewardship Institute. 2004b. Household pharmaceutical waste: regulatory and management issues. San Francisco Department of the Environment. http://www.productstewardship.us/supportingdocs/Pharm_CAWasteMgmt.pdf
Quijano R. F. 2003. Elements of the precautionary principle. In J. A. Tickner (ed.), Precaution, environmental science, and preventive public policy. Island Press, Washington, Pages 21–27
Rönnefahrt I., J. Koschorreck, M. Kolossa-Gehring. 2003. Practical examples for risk management of pharmaceuticals in the framework of authorization, EnvirPharma, Lyon, France
Sacher F., F. T. Lange, H. J. Brauch, I. Blankenhorn. 2001. Pharmaceuticals in groundwaters. Analytical methods and results of a monitoring program in Baden-Wurtemburg, Germany. J Chromatogr A 938:199–210
Sanderson H., D. J. Johnson, C. J. Wilson, R. A. Brain, K. R. Solomon. 2003. Probabilistic hazards assessment of environmentally occurring pharmaceuticals: toxicity to fish, daphnids and algae by ECOSARS screening. Toxicol Lett 144:383–395
Sanderson H., D. J. Johnson, T. Reitsma, R. A. Brain, C. J. Wilson, K. R. Solomon. 2004. Ranking and prioritization of environmental risks of pharmaceuticals in surface waters. Regul Toxicol Pharmacol 39:158–183
Schulman L. J., E. V. Sargent, B. D. Naumann, E. C. Faria, D. G. Dolan, J. P. Wargo. 2002. A human health risk assessment of pharmaceuticals in the aquatic environment. Hum Ecol Risk Assess 8:657–680
Sedlak D. L., K. E. Pinkston. 2001. Factors affecting the concentrations of pharmaceuticals released to the aquatic environment. Water Resources Update 120:56–64
SIGRE. 2002. Por la salud de la naturaleza: Memoria de actividades, 31 pp
Slovic P. 1993. Perceived risk, trust, and democracy. Risk Analysis 13:675–682
Stan H. J., T. Heberer, M. Linkerhagner. 1994. Vorkommen von Clofibrinsaure im aquatischen System—Fuhrt die therapeutische Anwendung zu einer Belastung von Oberflachen-, Grund- und Trinkwasser? Vom Vasser 79:57–68
Stockholm läns landsting. 2005. Environmentally classified pharmaceuticals, Stockholm, 16 pp
Stumpf M., T. A. Ternes, R. D. Wilken, S. V. Rodrigues, W. Baumann. 1999. Polar drug residues in sewage and natural waters in the state of Rio de Janeiro, Brazil. Sci Total Envir 225:135–141
Ternes T. A. 1998 Occurrence of drugs in German sewage treatment plants and rivers. Water Res 32:3245–3260
Ternes T. A., J. Stüber, N. Herrmann, D. McDowell, A. Ried, M. Kampmann, B. Teiser. 2003. Ozonation: a tool for removal of pharmaceuticals, contrast media and musk fragrances from wastewater? Water Res 37:1976–1982
The Presidential/Congressional Commission on Risk Assessment and Risk Management. 1997 Framework for environmental health risk management: final report, volume 1. US EPA, 70 pp
United Nations General Assembly. 1992. Report of the United Nations conference on environment and development. A/CONF.151/26 Vol. I, Rio de Janeiro, 5 pp
von Krauss M. P. K., E. A. Casman, M. J. Small. 2004. Elicitation of expert judgments of uncertainty in the risk assessment of herbicide-tolerant oilseed crops. Risk Analysis 24:1515–1527
Webb S., T. A. Ternes, M. Gibert, K. Olejniczak. 2003. Indirect human exposure to pharmaceuticals via drinking water. Toxicol Lett 142:157–167
Wennmalm Å. 2003. Management of pharmaceutical drug residues from public health care in Stockholm County Council, Envirpharma Conference, Lyon
Westerhoff P., Y. Yoon, S. A. Snyder, E. Wert. 2005. Fate of endocrine-disruptors, pharmaceutical, and personal care product chemicals during simulated drinking water treatment processes. Envir Sci Technol 39:6649–6663
Weterings R. A. P. M., J. C. M. Van Eijndhoven. 1989. Informing the public about uncertain risks. Risk Analysis 9:473–482
Wiegel S., A. Aulinger, R. Brockmeyer, H. Harms, J. Löffler, H. Reincke, R. Schmidt, B. Stachel, W. von Tümpling, A. Wanke. 2004. Pharmaceuticals in the river Elbe and its tributaries. Chemosphere 57:107–126
Wiener J. B., M. D. Rogers. 2002. Comparing precaution in the United States and Europe. J Risk Res 5:317–349
Wilson B. A., V. H. Smith, F. J. Denoyelles, C. K. Larive. 2003. Effects of three pharmaceutical and personal care products on natural freshwater algal assemblages. Envir Sci Technol 37:1713–1719
Wolf L., I. Held, M. Eiswirth, H. Hötzl. 2004. Impact of leaky sewers on groundwater quality. Acta Hydrochim Hydrobiol 32:361–373
Zwiener C., F. H. Frimmel. 2000. Oxidative treatment of pharmaceuticals in water. Water Research 34:1881–1885
Acknowledgments
Many thanks to the interviewees who generously gave their time to participate in this study. We also extend our appreciation to the Pierre Elliott Trudeau Foundation, which provided a travel grant for this study, in addition to a doctoral scholarship, and to the Social Sciences and Humanities Research Council of Canada (SSHRC), for also providing funding in the form of a doctoral scholarship.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Doerr-MacEwen, N.A., Haight, M.E. Expert Stakeholders’ Views on the Management of Human Pharmaceuticals in the Environment. Environmental Management 38, 853–866 (2006). https://doi.org/10.1007/s00267-005-0306-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00267-005-0306-z